Veru (NASDAQ:VERU) Now Covered by Westpark Capital

Equities researchers at Westpark Capital began coverage on shares of Veru (NASDAQ:VERU – Get Free Report) in a note issued to investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating on the stock.

A number of other equities analysts also recently commented on the company. Wall Street Zen downgraded Veru from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.50.

Get Veru alerts:

Check Out Our Latest Report on Veru

Veru Price Performance

NASDAQ:VERU traded down $0.08 during mid-day trading on Tuesday, reaching $2.47. The stock had a trading volume of 1,517,504 shares, compared to its average volume of 736,582. The company has a market capitalization of $42.11 million, a price-to-earnings ratio of -3.58 and a beta of -1.21. Veru has a 1-year low of $2.05 and a 1-year high of $7.33. The stock’s 50 day simple moving average is $2.53 and its two-hundred day simple moving average is $2.53.

Veru (NASDAQ:VERU – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Sell-side analysts anticipate that Veru will post -1.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Veru

Institutional investors and hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new position in shares of Veru during the 2nd quarter valued at $328,000. Renaissance Technologies LLC acquired a new position in Veru during the 1st quarter worth $153,000. Finally, Royal Bank of Canada lifted its position in Veru by 69.3% during the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after acquiring an additional 5,008 shares during the last quarter. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Veru Company Profile

(Get Free Report)

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.

Featured Stories

• Five stocks we like better than Veru
• Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
• Lamb Weston’s Turnaround Is Starting to Look Real
• These 3 Stocks Got the Most Love From Analysts in September
• Record French Debt Could Create Opportunities for U.S. Market Operators

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.